Medical Cannabis and Pregnancy: What the Evidence Says

Why Pregnancy Is a High-Risk Category

• THC is lipophilic and crosses the placenta readily, with foetal blood concentrations reaching approximately 10-30% of maternal levels
• The endocannabinoid system plays a critical role in early neurodevelopment, including synaptic formation, axonal growth, and cortical organisation
• Exogenous cannabinoids introduced during pregnancy may disrupt these developmental processes at sensitive windows that cannot be recovered
• Both CBD and THC reach the developing foetus; there is no evidence that CBD is safe in pregnancy, despite its generally more benign profile outside of pregnancy

Pregnancy is the clearest contraindication to medical cannabis use, and both patients and prescribers must approach this category with an exceptionally high standard of caution.

Risks Identified in Epidemiological Research

• Population studies consistently associate prenatal cannabis exposure with lower birth weight, increased risk of preterm birth, and higher rates of stillbirth
• Longitudinal cohort studies including the ABCD study (US) and ALSPAC (UK) show associations between prenatal cannabis exposure and increased childhood ADHD, anxiety, and cognitive impairment
• More potent modern cannabis products may carry proportionally greater risk than the lower-potency cannabis used in studies conducted before the early 2000s
• The evidence is observational and confounded by socioeconomic factors, poly-substance use, and tobacco co-exposure, but the pattern is sufficiently consistent to justify strong caution

While establishing causation is methodologically challenging in this population, the volume and consistency of epidemiological evidence is sufficient to justify treating prenatal cannabis exposure as genuinely hazardous.

What UK Guidance Recommends

• NICE, the Royal College of Obstetricians and Gynaecologists, and the Royal Pharmaceutical Society all advise against cannabis use in pregnancy
• Healthcare providers should ask about cannabis use during pregnancy without stigma, as non-disclosure is common and prevents appropriate support
• Women who are using cannabis for medical conditions must be supported to find alternative management strategies before conception or immediately upon discovering pregnancy
• The legal status of cannabis is not a protective factor; the biological risks apply equally to prescribed medical cannabis and illicitly sourced recreational cannabis

UK guidance from multiple professional bodies is clear and consistent: cannabis use in any form should be stopped before conception and avoided throughout pregnancy, with alternative treatments sought for any underlying conditions.

For Women Seeking Medical Cannabis Postpartum

• After delivery, the risks specific to pregnancy no longer apply, but breastfeeding introduces a separate concern requiring independent assessment
• Women who wish to resume medical cannabis after a pregnancy should return to their prescribing clinician for a fresh clinical assessment
• The postpartum period can bring significant challenges including pain, sleep disruption, and mood disorders that medical cannabis may be able to address safely once breastfeeding has concluded
• Family planning decisions are important to discuss with the cannabis prescriber, as current guidance recommends discontinuing before attempting to conceive

Postpartum women who have benefited from medical cannabis before or after their pregnancy should have access to a clear pathway for resuming treatment safely, supported by specialist prescribing guidance.